scholarly journals Salvage Resection of Mediastinal Nonseminomatous Germ Cell Tumor in a Patient with Extrathoracic Involvement upon Progression following High-Dose Chemotherapy

2021 ◽  
pp. 1254-1260
Author(s):  
Jia-Ling Chou ◽  
David Tse

Primary mediastinal nonseminomatous germ cell tumor with extrathoracic metastases is associated with a very high mortality rate, and there is no consensus regarding optimal upfront therapy. Once patients fail the first-line treatment, salvage therapy often fails to effectively control the disease. Resection of the residual mediastinal mass does not appear to achieve long-term control in those who have extrathoracic metastases following conventional first-line systemic therapy. We report a case where a young man presented with symptomatic brain metastases as well as extensive visceral involvement of the liver, small intestine, and lungs. He was successfully managed with multimodality treatment including high-dose chemotherapy with hematopoietic stem cell support following standard first-line chemotherapy, resection of mediastinal disease, lung metastasectomy, and stereotactic brain radiation. He has achieved long-term survival.

2005 ◽  
Vol 130 (4) ◽  
pp. 1205-1206 ◽  
Author(s):  
Hiroshi Date ◽  
Kiura Katsuyuki ◽  
Hiroshi Ueoka ◽  
Masahiro Tabata ◽  
Katsuyuki Hotta ◽  
...  

2011 ◽  
Vol 29 (3) ◽  
pp. 284-290 ◽  
Author(s):  
Ugo De Giorgi ◽  
Giovanni Rosti ◽  
Roberto Salvioni ◽  
Giorgio Papiani ◽  
Michela Ballardini ◽  
...  

2019 ◽  
Vol 142 (3) ◽  
pp. 523-528 ◽  
Author(s):  
Dana L. Casey ◽  
Kenneth L. Pitter ◽  
Brandon S. Imber ◽  
Andrew Lin ◽  
Timothy A. Chan ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 398-398
Author(s):  
Orvar Gunnarsson ◽  
Wei-Ting Hwang ◽  
Christian Michael Squillante ◽  
Katherine L. Nathanson ◽  
Edward A. Stadtmauer ◽  
...  

398 Background: The optimal management of patients with metastatic germ cell tumor (GCT) who experience progression after first-line (FL) therapy is controversial. A risk-stratified approach was introduced in 2005. Favorable risk patients received 4 cycles of paclitaxel, ifosfamide, cisplatin (TIP); unfavorable risk patients received 2 cycles of TIP followed by 2 cycles of high-dose chemotherapy [(HDCT); carboplatin and etoposide with autologous stem cell support]. Favorable risk was generally defined as gonadal primary and relapse > 6 months after CR or marker negative PR to FL therapy; all others were unfavorable risk. The aim of this study is to present survival outcome of this risk-stratified approach at a single institution. Methods: A chart-based retrospective review was conducted on all patients with metastatic GCT who experienced progression after FL therapy from 2005 to 2013. Data were collected on baseline demographics and disease characteristics. Progression-free survival (PFS) and overall survival (OS) were calculated for favorable and unfavorable risk patients. Results: 37 patients were identified and included for analysis. Patients characteristics: Caucasian 92%; median age 27 years; gonadal primary 84%; non-seminoma, 81%. 16 (43%) favorable risk patients received TIP x 4; 21 (57%) unfavorable risk patients received TIP x 2 followed by HDCT x 2. The median time for follow-up was 16 months. Favorable risk patients: 2- and 4-year PFS of 60% and 45%; 2- and 4-year OS of 74%. Unfavorable risk patients: 2- and 4-year PFS of 41% and 27%; 2- and 4-year OS of 55% and 34%. Both IGCCCG risk classification at initial diagnosis and IPFSG risk classification at relapse had prognostic validity for OS (log rank p ≤ 0.05) but not PFS (log rank p = 0.065–0.080). Conclusions: Risk-stratified treatment of patients with metastatic GCT with progression after FL therapy may result in the best risk/benefit ratio. However, the optimal management of these patients is still not known and prospective randomized comparisons are needed.


Sign in / Sign up

Export Citation Format

Share Document